AR091951A1 - Vesiculas que comprenden factor de crecimiento epidermico y composiciones que las contienen - Google Patents

Vesiculas que comprenden factor de crecimiento epidermico y composiciones que las contienen

Info

Publication number
AR091951A1
AR091951A1 ARP130102727A ARP130102727A AR091951A1 AR 091951 A1 AR091951 A1 AR 091951A1 AR P130102727 A ARP130102727 A AR P130102727A AR P130102727 A ARP130102727 A AR P130102727A AR 091951 A1 AR091951 A1 AR 091951A1
Authority
AR
Argentina
Prior art keywords
vesicles
cholesterol
derivatives
cationic surfactant
egf
Prior art date
Application number
ARP130102727A
Other languages
English (en)
Inventor
Ventosa Rull Leonor
Jesus Santana Milian Hector
Cabrera Puig Ingrid
Veciana Miro Jaume
Martinez Diaz Eduardo
Amador Berlanga Acosta Jorge
Original Assignee
Ct Ingenieria Genetica Biotech
Consejo Superior Investigacion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49118249&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR091951(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ct Ingenieria Genetica Biotech, Consejo Superior Investigacion filed Critical Ct Ingenieria Genetica Biotech
Publication of AR091951A1 publication Critical patent/AR091951A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41—Amines
    • A61K8/416—Quaternary ammonium compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0066—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/805—Corresponding aspects not provided for by any of codes A61K2800/81 - A61K2800/95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A61L2300/414—Growth factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Diabetes (AREA)
  • Materials Engineering (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)

Abstract

Vesículas que comprenden el Factor de Crecimiento Epidérmico (EGF), un surfactante catiónico, y colesterol o sus derivados. Procedimiento para su preparación, basado en la tecnología de fluidos comprimidos (FCs). Las vesículas tienen utilidad en la fabricación de medicamentos y productos cosméticos, y en la ingeniería tisular. Reivindicación 3: Las vesículas de la reivindicación 2 donde el surfactante catiónico de tipo amonio cuaternario es un surfactante seleccionado del grupo compuesto por bromuro de cetiltrimetilamonio (CTAB), cetrimida y cloruro de benzalconio (BKC). Reivindicación 4: Las vesículas de las reivindicaciones 1 - 3 donde la proporción molar entre el surfactante catiónico y el colesterol, o sus derivados, se encuentra en el rango de 10M:1M a 1M:5M; y la proporción molar entre el EGF y el colesterol, o sus derivados, se encuentra en el rango de 0,5mM:1M a 100mM:1M. Reivindicación 5: Las vesículas de las reivindicaciones 1 - 4 que se caracterizan porque presentan estructura unilamelar y tamaño medio aproximado entre 25 y 500 nm, preferentemente entre 50 y 300 nm. Reivindicación 10: Proceso para la preparación de vesículas que comprenden el EGF, un surfactante catiónico y colesterol, o sus derivados, que se caracteriza porque comprende: a) la preparación de una disolución acuosa de EGF y un surfactante catiónico, b) la disolución de colesterol o sus derivados en un disolvente orgánico expandido con un FC, c) la síntesis de las vesículas mediante la despresurización de la disolución resultante de la etapa b) sobre la disolución resultante de la etapa a). Reivindicación 12: El proceso de la reivindicación 10 donde el disolvente orgánico de la etapa b) es un disolvente que se selecciona del grupo compuesto por los alcoholes monohídricos, los alcoholes polihídricos, las cetonas, la etilendiamina, el acetonitrilo, el acetato de etilo y mezclas de ellos. Reivindicación 13: El proceso de la reivindicación 10 donde el FC es un compuesto que se selecciona entre el dióxido de carbono, el etano, el propano, los hidroclorofluorocarbonos, y los hidrofluorocarbonos. Reivindicación 17: Composición farmacéutica que se caracteriza porque comprende las vesículas de cualquiera de las reivindicaciones 1 - 9, y al menos un excipiente farmacéuticamente aceptable. Reivindicación 18: La composición de la reivindicación 17 que se caracteriza porque puede ser administrada por vía sistémica, intralesional, mucosal, tópica, transdérmica, o oftálmica, o como formulación inhalada. Reivindicación 21: El uso de la reivindicación 20 donde la herida compleja es una úlcera del pie diabético. Reivindicación 25: El uso de la reivindicación 24 donde el medicamento se utiliza para el tratamiento de la mucositis, colitis ulcerativa, úlceras duodenales, o colitis distal. Reivindicación 29: El uso de la reivindicación 28 donde el producto cosmético es un producto para prevenir la senescencia y el envejecimiento de la piel.
ARP130102727A 2012-08-02 2013-08-01 Vesiculas que comprenden factor de crecimiento epidermico y composiciones que las contienen AR091951A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CUP2012000112A CU24121B1 (es) 2012-08-02 2012-08-02 Vesículas que comprenden factor de crecimiento epidérmico y composiciones que las contienen

Publications (1)

Publication Number Publication Date
AR091951A1 true AR091951A1 (es) 2015-03-11

Family

ID=49118249

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130102727A AR091951A1 (es) 2012-08-02 2013-08-01 Vesiculas que comprenden factor de crecimiento epidermico y composiciones que las contienen

Country Status (27)

Country Link
US (2) US9717776B2 (es)
EP (1) EP2915541B1 (es)
JP (1) JP6251740B2 (es)
KR (1) KR101752757B1 (es)
CN (1) CN104684575B (es)
AR (1) AR091951A1 (es)
AU (1) AU2013299036C1 (es)
BR (1) BR112015002103B1 (es)
CA (1) CA2880404C (es)
CL (1) CL2015000254A1 (es)
CU (1) CU24121B1 (es)
DK (1) DK2915541T3 (es)
ES (1) ES2613087T3 (es)
HK (1) HK1210970A1 (es)
HR (1) HRP20170145T1 (es)
HU (1) HUE033286T2 (es)
MX (1) MX360674B (es)
MY (1) MY196771A (es)
PL (1) PL2915541T3 (es)
PT (1) PT2915541T (es)
RS (1) RS55713B1 (es)
RU (1) RU2649781C2 (es)
SG (1) SG11201500797SA (es)
SI (1) SI2915541T1 (es)
UA (1) UA113448C2 (es)
WO (1) WO2014019555A1 (es)
ZA (1) ZA201500763B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3241565A4 (en) * 2014-12-30 2018-07-18 Celltrion, Inc. Hybrid-type multi-lamellar nanostructure of epidermal growth factor and liposome and method for manufacturing same
EP3270984A4 (en) * 2015-03-16 2019-04-17 Duncan Ross TREATMENT METHOD WITH MEMBRANE-INCLUDED VESICLE
WO2017123022A1 (ko) * 2016-01-12 2017-07-20 주식회사 강스템바이오텍 고함량의 성장인자를 함유한 줄기세포 유래 엑소좀
WO2017147407A1 (en) 2016-02-25 2017-08-31 Board Of Regents, The University Of Texas System Compositions comprising composite nanocarriers and methods of making and uses thereof
US11241480B2 (en) * 2017-01-26 2022-02-08 Washington University Methods for modulation of dietary and microbial exposure with compositions comprising an EGFR ligand
TWI636794B (zh) * 2017-11-06 2018-10-01 吳治增 一種奈米複合材料及其應用
CU20190022A7 (es) * 2019-03-18 2020-10-20 Centro De Ingenieria Genetica Y Biotecnologia Biocubafarma Composición farmacéutica para el tratamiento de la úlcera del pie diabético
WO2021206328A1 (ko) * 2020-04-10 2021-10-14 한국과학기술연구원 신규 재조합 엑소좀 및 그의 용도
CN113827622B (zh) * 2021-08-31 2023-11-07 南方医科大学 奇异变形杆菌外膜囊泡在制备预防或治疗骨溶解性疾病药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0272123A (ja) * 1988-09-07 1990-03-12 Hitachi Chem Co Ltd ヒト上皮細胞成長因子の投与方法及びヒト上皮細胞成長因子含有疾病治療剤
US4944948A (en) 1989-02-24 1990-07-31 Liposome Technology, Inc. EGF/Liposome gel composition and method
US5064655A (en) * 1989-02-24 1991-11-12 Liposome Technology, Inc. Liposome gel composition and method
US5618544A (en) 1992-08-12 1997-04-08 Bays-Brown Dermatologics, Inc. Method of decreasing cutaneous senescence
US20020081324A1 (en) * 2002-01-22 2002-06-27 Twine Rebecca Wright Method of treating aging skin and wrinkles using a combination of growth factors that is commercially prepared or derived from one's own blood
AU2003222668A1 (en) * 2002-04-25 2003-11-10 Rapidheal, Inc. Growth factor delivery system for the healing of wounds and the prevention of inflammation and disease
ES2265262B1 (es) * 2005-01-31 2008-03-01 Activery Biotech, S.L.(Titular Al 50%) Procedimiento para la obtencion de sistemas micro- y nanodispersos.
WO2007065464A1 (en) 2005-12-09 2007-06-14 Stichting Katholieke Universiteit Epidermal growth factor (egf) derivatives with selectable selectivity for the erb receptor family
CU23411B6 (es) * 2005-12-29 2009-09-08 Ct Ingenieria Genetica Biotech Uso tópico del factor de crecimiento epidérmico en liposomas para prevenir la amputación del pie diabético
JP2009234945A (ja) * 2008-03-26 2009-10-15 Shalom:Kk ｈ−ＥＧＦ含有スフィンゴミエリンリポソームおよびこれを配合した化粧料及び医薬品
CN102091034A (zh) * 2009-12-15 2011-06-15 哈尔滨工业大学 基于胆固醇衍生物的有机-无机复合纳米囊泡的制备
KR101102834B1 (ko) * 2010-02-24 2012-01-05 충남대학교산학협력단 신규한 리포좀 제조 방법 및 장치
WO2011138687A2 (en) * 2010-05-06 2011-11-10 Regenics As Use of cellular extracts for skin rejuvenation

Also Published As

Publication number Publication date
SG11201500797SA (en) 2015-03-30
AU2013299036B2 (en) 2017-12-14
CA2880404C (en) 2018-02-13
CL2015000254A1 (es) 2015-10-16
AU2013299036A1 (en) 2015-03-19
CU20120112A7 (es) 2014-03-26
HRP20170145T1 (hr) 2017-04-07
DK2915541T3 (en) 2017-02-13
JP6251740B2 (ja) 2017-12-20
HK1210970A1 (en) 2016-05-13
JP2015527337A (ja) 2015-09-17
MY196771A (en) 2023-05-03
BR112015002103B1 (pt) 2022-11-29
SI2915541T1 (sl) 2017-05-31
RU2015106683A (ru) 2016-09-27
KR20150041795A (ko) 2015-04-17
PT2915541T (pt) 2017-02-13
MX360674B (es) 2018-11-13
CN104684575B (zh) 2018-07-31
US9717776B2 (en) 2017-08-01
MX2015001561A (es) 2015-09-29
CN104684575A (zh) 2015-06-03
CA2880404A1 (en) 2014-02-06
PL2915541T3 (pl) 2017-06-30
BR112015002103A2 (pt) 2019-08-20
KR101752757B1 (ko) 2017-07-04
WO2014019555A1 (es) 2014-02-06
US20180015145A1 (en) 2018-01-18
ES2613087T3 (es) 2017-05-22
UA113448C2 (xx) 2017-01-25
AU2013299036C1 (en) 2018-03-29
RS55713B1 (sr) 2017-07-31
ZA201500763B (en) 2016-01-27
US20150182590A1 (en) 2015-07-02
HUE033286T2 (en) 2017-11-28
US11510965B2 (en) 2022-11-29
RU2649781C2 (ru) 2018-04-04
EP2915541A1 (en) 2015-09-09
EP2915541B1 (en) 2016-11-09
CU24121B1 (es) 2015-08-27

Similar Documents

Publication Publication Date Title
AR091951A1 (es) Vesiculas que comprenden factor de crecimiento epidermico y composiciones que las contienen
AR124134A2 (es) Formulación de uso tópico para un inhibidor de jak
US9271930B2 (en) Dermatological foams obtained from a gel or suspension containing adapalene
CL2011001468A1 (es) Uso de una composicion libre de ingredientes activos farmaceuticos que consiste en triglicerido caprilico/caprico, alcohol cetoestearilico, estearato de glicerilo, acido benzoico, estearato de peg-40, mc, goma xantano, polisorbato 80, dimetil isosorbida, propilenglicol, naoh, agua y propulsor para tratar rosacea, acne o psoriasis.
ES2625747T3 (es) Composición para limpieza personal que comprende agentes gelificantes y de formación de espuma para la impregnación de tejido
BR112015012565A2 (pt) composto, composição cosmética ou farmacêutica, e, uso de um composto
ECSP13013010A (es) Preparación de gadobutrol de alta pureza
GT200600096A (es) Composicion farmaceutica para el tratamiento del cancer
BR112012030653A2 (pt) composição tópica em aerosol, estável ao armazenamento e substancialmente anidra, e, recipiente pressurizado
AR090349A1 (es) Terapia de combinacion para trastornos proliferativos, kit y uso
EP3413919A1 (en) Compositions containing cyclodextrin-based metal organic frameworks
AR086409A1 (es) Formulaciones de gel bioadhesivo de testosterona intranasal y uso del mismo para tratar hipogonadismo masculino
PH12017500136A1 (en) Long-chain dimethylaniline derivative compounds, their preparation methods, self-assembled textures, and uses thereof
CO6430467A2 (es) Péptidos útiles en el tratamiento y/o cuidado de la piel y/o cabello y su uso en composiciones cosméticas o farmacéuticas
WO2016154232A3 (en) Pharmaceutical tetracycline composition for dermatological use
BR112012029628A2 (pt) formulações lipossômicas melhoradas de compostos lipofílicos
WO2017037593A3 (zh) 用于减少局部脂肪的医药组成物及其用途
MX354480B (es) Composiciones espumables de peróxido de benzoilo para administración tópica.
AR092685A1 (es) Formulaciones espumantes de cuidado de la piel
AR065317A1 (es) Uso de quitosanos, derivados de quitosanos y una sal fisiologicamente aceptable del mismo para el tratamiento de enfermedades inflamatorias ungueales
ES2702576T3 (es) Composición de gel de lavado de BPO
US20130317108A1 (en) Dermatological foams obtained from a gel or suspension containing a combination of adapalene and benzoyl peroxide
US20130338235A1 (en) Dermatological foams obtained from a gel or suspension containing benzoyl peroxide
JP2016521746A5 (es)
AR065316A1 (es) Uso de quitosanos, derivados de quitosanos y una sal fisiologiamente aceptable del mismo para el tratamiento de enfermedades inflamatorias ungueales

Legal Events

Date Code Title Description
FC Refusal